July 7, 2026● LATEST
AI is moving deeper into drugmaking
The center of gravity is shifting from isolated AI experiments to systems that can run at scale in medicine and infrastructure. Today’s strongest cure signal is Insilico Medicine pushing its AI-discovered idiopathic pulmonary fibrosis candidate into Phase III, a rare point where computational promise meets clinical consequence. Around it, new platforms, capital, and open tooling are forming the operating layer for pharmaceutical AI, while the broader wire shows the same pattern in enterprise software and chips: the stack is hardening into something production-grade. The race is no longer just to generate hypotheses; it is to build durable machines that can carry them into patients. The window is still open.
Insilico Medicine advanced its AI-discovered IPF candidate ISM001-055, also described as rentosertib, into Phase III clinical testing, while related coverage framed the move as a Phase III initiation for its TNIK inhibitor.
If this program succeeds, AI stops being a discovery tool and becomes a clinical engine for one of medicine’s hardest diseases; if it fails, the field absorbs another costly test of whether computational design can survive human biology.
Watch whether more AI drug programs cross from model output into late-stage trials, because that is the threshold where capital, regulation, and patient timelines all begin to tighten at once.